U.S government orders 100 million doses of Moderna’s vaccine, yet insiders are selling – here’s what you need to know

Moderna (NASDAQ: MRNA), alongside Novavax, is running at full speed in the vaccine race. The Trump Administration’s recent agreement with Moderna to order 100 million doses adds to the argument that MRNA is at the front of the pack. While the announcement is a positive catalyst, investors are doubtful that we will see an enormous rally.…

Actinium Pharmaceuticals hits 150% gain over 2 months – here’s everything you need to know

Actinium Pharmaceuticals (NYSE:ATNM) has caught the attention of investors as the stock continues its path of strong bullish momentum. ATNM is likely to open at $0.56 according to pre-market movements, marking a 211% gain over the past 2 months. The Bio-Pharma works on the development of commercial therapies for bone marrow transplant and other adoptive cell therapies.…

Moderna set to surge after producing positive trial results for COVID-19 vaccine

Moderna announced this morning that their interim Phase 1 data for COVID-19 vaccine has shown positive results. The company has been heavily watched by investors and speculators alike – as their vaccine (mRNA-1273) continues to show positive signs. The announcement confirmed the Biomedical Advanced Research and Development Authority (BARDA) are in support of the companies phase 2 and 3 trials, as well as scaling up the manufacturing of the vaccine.…